DaVita Inc.
Net earnings for the quarter and six months ended June 30, 2001, including recoveries and the extraordinary gain, were $29.5 million or $0.33 per share and $60.5 million or $0.68 per share, respectively.
Financial and operating highlights include:
-- Continental U.S. dialysis revenue per treatment (excluding lab,
management fees and other revenue) in the second quarter was $275.87 as
compared to $274.22 in the first quarter, or a .6% sequential increase.
-- Continental U.S. DSO at quarter end was 68 days compared to 71 days at
the end of the first quarter.
-- The continental U.S. EBITDA margin, excluding the cash recoveries, for
the second quarter was 22.3% as compared to 22.5% for the first quarter
of 2001.
-- Operating cash flow for the three months and six months ended
June 30, 2001 was $77 million and $135 million, respectively.
-- Total continental U.S. treatments for the second quarter were
1,409,320. Both non-acquired and same center treatment growth were
2.8%.
-- At June 30, 2001 we operated 488 outpatient centers in the continental
U.S. serving 42,000 patients. During the quarter we closed one
under-performing center and opened two de novo centers. Included in our
continental patient and center count are 3,300 patients in 35 centers
under management.
DaVita will hold a conference call to discuss its second quarter 2001 results on Thursday, August 2, 2001 at 10:30 a.m. Pacific time, 1:30 p.m. Eastern time. The dial-in number is +1-800-399-4406. A replay of the conference call will be available on DaVita's official web page, http://www.davita.com/ for the following 90 days.
This release contains forward-looking statements. Factors which could impact future results include the uncertainties associated with governmental regulation, general economic and other market conditions, and the risk factors set forth in the Company's SEC filings, including its Form 10-K/A for the year ended December 31, 2000. These risks include those relating to (1) possible reductions in private and government reimbursement rates, (2) the concentration of profits generated from PPO and private indemnity patients and from ancillary services including pharmaceuticals, (3) the ongoing payment suspension and review of the Company's Florida laboratory subsidiary by its Medicare carrier and the Department of Justice, (4) the ongoing review by the Civil Division of the US Attorney's Office for the Eastern District of Pennsylvania and (5) the Company's ability to maintain contracts with physician medical directors. The forward-looking statements should be considered in light of these risks and uncertainties.
DAVITA INC.
CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except per share data)
June 30, December 31,
2001 2000
ASSETS
Cash and cash equivalents $85,258 $31,207
Accounts receivable, less allowance
of $53,551 and $61,619 297,907 290,412
Inventories 44,604 20,641
Other current assets 12,726 10,293
Income taxes receivable 2,830
Deferred income taxes 42,846 42,492
Total current assets 483,341 397,875
Property and equipment, net 241,538 236,659
Intangible assets, net 945,821 921,623
Investments in third-party dialysis businesses 11,206 34,194
Other long-term assets 2,117 1,979
Deferred income taxes 4,302
$1,684,023 $1,596,632
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable $ 79,227 $ 74,882
Other current liabilities 116,066 102,563
Accrued compensation and benefits 83,166 70,406
Current portion of long-term debt 15,419 1,676
Income taxes payable 689
Total current liabilities 294,567 249,527
Long-term debt 935,247 974,006
Other long-term liabilities 4,984 4,855
Deferred taxes 521
Minority interests 21,125 18,876
Shareholders' equity:
Preferred stock ($0.001 par value;
5,000,000 shares authorized; none issued
or outstanding)
Common stock ($0.001 par value,
195,000,000 shares authorized;
84,135,381 and 82,135,634 shares
issued and outstanding) 84 82
Additional paid-in capital 450,817 430,676
Notes receivable from shareholders (83)
Treasury stock, at cost (126,000 shares) (2,494)
Accumulated deficit (20,828) (81,307)
Total shareholders' equity 427,579 349,368
$1,684,023 $1,596,632
DAVITA INC.
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(dollars in thousands, except per share data)
Three months ended Six months ended
June 30, June 30,
2001 2000 2001 2000
Net operating revenues $400,640 $378,908 $786,857 $751,021
Operating expenses:
Dialysis centers and labs 271,545 267,714 532,519 527,012
General and administrative 32,417 31,619 64,230 63,540
Depreciation and
amortization 26,624 29,670 52,772 57,388
Provision for uncollectible
accounts (378) 12,648 (8,563) 25,507
Impairment and valuation
adjustments 4,414 4,414
Total operating expenses 330,208 346,065 640,958 677,861
Operating income 70,432 32,843 145,899 73,160
Other income, net 1,120 (11,984) 2,468 (10,589)
Debt expense 18,715 34,482 38,439 67,647
Minority interests in income
of consolidated subsidiaries (2,269) (1,023) (4,726) (2,021)
Income before income taxes 50,568 (14,646) 105,202 (7,097)
Income tax expense 22,000 709 45,700 4,411
Income (loss) before
extraordinary item 28,568 (15,355) 59,502 (11,508)
Extraordinary gain related
to early extinguishment of
debt, net of tax of $652 977 977
Net income (loss) $29,545 $(15,355) $60,479 $(11,508)
Earnings (loss) per common
share-basic:
Income (loss) before
extraordinary item $0.34 $(0.19) $0.72 $(0.14)
Extraordinary gain, net of tax 0.01 0.01
Net income (loss) $0.35 $(0.19) $0.73 $(0.14)
Weighted average number
of common shares
outstanding 83,548,000 81,438,000 82,997,000 81,376,000
Earnings (loss) per common
share-assuming dilution:
Income (loss) before
extraordinary item $0.32 $(0.19) $0.67 $(0.14)
Extraordinary gain, net of tax 0.01 0.01
Net income (loss) $0.33 $(0.19) $0.68 $(0.14)
Weighted average number
of common shares outstanding
- assuming dilution 92,693,000 81,438,000 92,262,000 81,376,000
Supplemental information excluding recoveries, impairments and
extraordinary item:
Continental treatments 1,409,320 1,335,873 2,775,788 2,653,389
Continental EBITDA $88,510 $62,306 $174,539 $124,845
Earnings per common
share - assuming dilution $0.26 $0.03 $0.51 $0.07
SOURCE: DaVita, Inc.
Contact: LeAnne Zumwalt, Investor Relations of DaVita Inc.,
+1-310 750-2072
Website: http://www.davita.com/